Reply to Jack E. Riggs' "Deprenyl, excess mortality, and epidemiological traps". Parkinson's Disease Research Group of the United Kingdom.
Head
J
J
Ben-Shlomo
Y
Y
Lees
A J
AJ
D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000978:Antiparkinson Agents / Q000627:therapeutic use; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy* / Q000453:epidemiology / Q000401:mortality*; D016016:Proportional Hazards Models; D016032:Randomized Controlled Trials as Topic; D012642:Selegiline / Q000627:therapeutic use; D016896:Treatment Outcome
D000978:Antiparkinson Agents; D012642:Selegiline; D007980:Levodopa